Patents by Inventor Matthew Forrest
Matthew Forrest has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11926642Abstract: The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.Type: GrantFiled: July 1, 2021Date of Patent: March 12, 2024Assignee: Pfizer inc.Inventors: Robert Steven Kania, Padmavani Bezawada, Emma Louise Hawking, Rohit Jaini, Samir Kulkarni, Matthew Nathan O'Brien Laramy, Jonathan Richard Lillis, Suman Luthra, Dafydd Rhys Owen, Klimentina Dimitrova Pencheva, Anil Mahadeo Rane, Matthew Forrest Sammons, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst, Jamison Bryce Tuttle, Robert Louis Hoffman
-
Patent number: 11807899Abstract: The invention relates to processes for performing biochemical reactions, such as in an aqueous in vitro reaction system. The processes involve macromolecules, particularly polypeptides, comprising one or more functional intrinsically disordered regions (IDRs). The invention also relates to IDR-macromolecules, including IDR-polypeptides, including macromolecules or polypeptides comprising a tagged amino acid sequence which comprises or consists of one or more functional IDRs. Such functional IDRs are capable of increasing the efficiency of the biochemical reaction. The invention relates to kits comprising any such macromolecules and polypeptides. The invention further relates to processes for stimulating or enhancing liquid-liquid demixing in a solution using any such macromolecules and polypeptides, including in combination with multivalent metal ions, thereby providing reagents capable of increasing the efficiency of a biochemical reaction.Type: GrantFiled: November 19, 2021Date of Patent: November 7, 2023Inventors: Niall Armes, Hannah Williams, Matthew Forrest, Mathew Parker, Sidong Liu, Lauren Parker
-
Publication number: 20230339930Abstract: The invention relates to compounds of Formula I wherein R1, R2, p, m, A, Z1, Z2, Z3 and Z4 are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.Type: ApplicationFiled: July 7, 2021Publication date: October 26, 2023Applicant: Pfizer Inc.Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Qingyi Yang
-
Publication number: 20230174532Abstract: Described herein are methods of treating MC4R-related conditions, diseases, or disorders by administering compounds of Formula I: or their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein. Such conditions, diseases, or disorders include cachexia, anorexia, or anorexia nervosa.Type: ApplicationFiled: January 31, 2023Publication date: June 8, 2023Applicant: Pfizer Inc.Inventors: Christopher Ryan BUTLER, Michelle Renee GARNSEY, Kevin Alexander OGILVIE, Jana POLIVKOVA, Matthew Forrest SAMMONS, Aaron Christopher SMITH, Qingyi Yang
-
Patent number: 11643412Abstract: Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.Type: GrantFiled: June 8, 2021Date of Patent: May 9, 2023Assignee: Pfizer Inc.Inventors: Christopher Ryan Butler, Michelle Renee Garnsey, Kevin Alexander Ogilvie, Jana Polivkova, Matthew Forrest Sammons, Aaron Christopher Smith, Qingyi Yang
-
Publication number: 20230120254Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.Type: ApplicationFiled: September 14, 2022Publication date: April 20, 2023Applicant: Pfizer Inc.Inventors: Dafydd Rhys Owen, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Qingyi Yang
-
Publication number: 20230120707Abstract: The invention relates to compounds of formula I wherein R1 and R2 are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compoundType: ApplicationFiled: March 31, 2021Publication date: April 20, 2023Applicant: Pfizer Inc.Inventors: Robert Steven Kania, Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Forrest Sammons, Jamison Bryce Tuttle
-
Publication number: 20230105838Abstract: The invention relates to methods of treating COVID-19 in a patient by administering therapeutically effective amounts of certain SARS-CoV-2 inhibitor compounds or pharmaceutical compositions containing them to a patient in need thereof. The invention also relates to inhibiting SARS-CoV-2 coronavirus viral replication activity comprising contacting SARS-CoV-2-related coronavirus protease with a therapeutically effective amount of a SARS-Cov-2 protease inhibitor, such as a SARS-Cov-2 3CL protease inhibitor and compositions comprising the same.Type: ApplicationFiled: April 1, 2021Publication date: April 6, 2023Applicant: Pfizer Inc.Inventors: Robert Louis Hoffman, Robert Steven Kania, Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Forrest Sammons, Jamison Bryce Tuttle
-
Publication number: 20230079835Abstract: An information processing device includes an obtaining section configured to obtain position information of a plurality of parts of a photographing target, a deriving section configured to derive a length between two parts, and a production control section configured to perform production on the basis of the derived length.Type: ApplicationFiled: September 13, 2022Publication date: March 16, 2023Applicants: Sony Interactive Entertainment Inc., Sony Interactive Entertainment LLC, Sony Group CorporationInventors: Yasushi OKUMURA, Daisuke KAWAMURA, Udupi Ramanath BHAT, Naoki OGISHITA, Goro TAKAKI, Shusuke ESHITA, Matthew FORREST
-
Publication number: 20230019853Abstract: Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.Type: ApplicationFiled: June 8, 2021Publication date: January 19, 2023Applicant: Pfizer Inc.Inventors: Christopher Ryan Butler, Michelle Renee Garnsey, Kevin Alexander Ogilvie, Jana Polivkova, Matthew Forrest Sammons, Aaron Christopher Smith, Qingyi Yang
-
Patent number: 11541034Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.Type: GrantFiled: December 17, 2021Date of Patent: January 3, 2023Assignee: Pfizer Inc.Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
-
Patent number: 11452711Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.Type: GrantFiled: April 22, 2022Date of Patent: September 27, 2022Assignee: Pfizer Inc.Inventors: Dafydd Rhys Owen, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Qingyi Yang
-
Publication number: 20220257563Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.Type: ApplicationFiled: April 22, 2022Publication date: August 18, 2022Applicant: Pfizer Inc.Inventors: Dafydd Rhys Owen, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Qingyi Yang
-
Patent number: 11351149Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.Type: GrantFiled: August 5, 2021Date of Patent: June 7, 2022Assignee: Pfizer Inc.Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
-
Publication number: 20220142976Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.Type: ApplicationFiled: December 17, 2021Publication date: May 12, 2022Applicant: Pfizer Inc.Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
-
Publication number: 20220145378Abstract: The invention relates to processes for performing biochemical reactions, such as in an aqueous in vitro reaction system. The processes involve macromolecules, particularly polypeptides, comprising one or more functional intrinsically disordered regions (IDRs). The invention also relates to IDR-macromolecules, including IDR-polypeptides, including macromolecules or polypeptides comprising a tagged amino acid sequence which comprises or consists of one or more functional IDRs. Such functional IDRs are capable of increasing the efficiency of the biochemical reaction. The invention relates to kits comprising any such macromolecules and polypeptides. The invention further relates to processes for stimulating or enhancing liquid-liquid demixing in a solution using any such macromolecules and polypeptides, including in combination with multivalent metal ions, thereby providing reagents capable of increasing the efficiency of a biochemical reaction.Type: ApplicationFiled: November 19, 2021Publication date: May 12, 2022Inventors: Niall ARMES, Hannah WILLIAMS, Matthew FORREST, Matthew PARKER, Sidong LIU, Lauren PARKER
-
Publication number: 20220112547Abstract: The invention relates to processes for performing biochemical reactions, such as in an aqueous in vitro reaction system. The processes involve macromolecules, particularly polypeptides, comprising one or more functional intrinsically disordered regions (IDRs). The invention also relates to IDR-macromolecules, including IDR-polypeptides, including macromolecules or polypeptides comprising a tagged amino acid sequence which comprises or consists of one or more functional IDRs. Such functional IDRs are capable of increasing the efficiency of the biochemical reaction. The invention relates to kits comprising any such macromolecules and polypeptides. The invention further relates to processes for stimulating or enhancing liquid-liquid demixing in a solution using any such macromolecules and polypeptides, including in combination with multivalent metal ions, thereby providing reagents capable of increasing the efficiency of a biochemical reaction.Type: ApplicationFiled: November 17, 2021Publication date: April 14, 2022Inventors: Niall ARMES, Hannah Williams, Matthew Forrest, Matthew Parker, Sidong Liu, Lauren Parker
-
Publication number: 20220062232Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.Type: ApplicationFiled: August 5, 2021Publication date: March 3, 2022Applicant: Pfizer Inc.Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
-
Patent number: D956080Type: GrantFiled: August 22, 2019Date of Patent: June 28, 2022Assignee: SONY CORPORATIONInventors: Sho Kobayashi, Matthew Forrest
-
Patent number: D1009898Type: GrantFiled: September 20, 2021Date of Patent: January 2, 2024Assignee: SONY GROUP CORPORATIONInventors: Hazime Matsuda, Matthew Forrest, Keiichi Yoshioka